Pharm small group: HIV 2 Flashcards Preview

Pharmacology > Pharm small group: HIV 2 > Flashcards

Flashcards in Pharm small group: HIV 2 Deck (14):
1

What is the MOA of protease inhibitors?

Prevent processing of viral proteins -> production of immature, noninfectious viral particles.

2

Are protease inhibitors active against HIV-2?

Yes... active against both HIV-1 and HIV-2.

3

Do protease inhibitors need intracellular activation?

No

4

What are the adverse effects associated with protease inhibitors?

Carbohydrate and Lipid metabolism disorders:
1) Hyperglycemia
2) Insulin resistance
3) Hyperlipidemia
4) Altered body fat distribution
5) Buffalo hump
6) Gynecomastia
7) Truncal obesity may occur with facial and peripheral lipodystrophy

5

Protease inhibitors are extensively metabolized by what?

CYP3A4

6

Which protease inhibitor is used as a pharmacokinetic enhancer due to its potent CYP3A4 inhibitory properties?

Ritonavir

7

Which anti-retroviral is an entry inhibitor? (2)

1) Enfuvirtide
2) Maraviroc

8

What is the A.E. of enfuvirtide?

local injection site reactions

9

What is the MOA of Raltegravir?

Inhibits integrase -> prevents integration of reverse transcribed HIV DNA into chromosomes of host cells

10

What are the adverse effects of Raltegravir?

1) Diarrhea
2) Nausea
3) Dizziness
4) Headache
5) Increases in creatine kinase

11

What is the preferred HIV regimen for a pregnant woman?

Lopinavir +
Low dose Ritonavir +
Zidovudine +
Lamivudine

12

What is the preferred NNRTI based regimen?

Efavirenz +
Tenofovir +
Emtricitabine

13

What is the preferred PI-based regimen?

Atazanavir OR Darunavir
+
Low Dose Ritonavir + Tenofovir + Emtricitabine

14

What is the preferred regimen for occupational post-exposure prophylaxis

Raltegravir + Tenogovir + Emtricitabine
for 28 days